Mauriac L, Durand M, Chauvergne J, Dilhuydy J M, Bonichon F
Fondation Bergonié, Comprehensive Cancer Center of Southwest of France, Bordeaux.
Ann Oncol. 1992 Jun;3(6):439-43. doi: 10.1093/oxfordjournals.annonc.a058231.
From January 1985 to December 1987, 228 women with breast cancer smaller than 3 cm were treated by surgery +/- radiotherapy. All of them had axillary node involvement (N+) and/or lacked estrogen and progesterone steroid receptors (EPR-). They were randomized in an adjuvant chemotherapy trial comparing 9 intravenous CMF courses (cyclophosphamide, methotrexate, 5FU)--113 patients--to a polychemotherapy consisting of 3 courses of MTV (mitomycin C, thiotepa, vindesine) plus 3 courses of EVM (epirubicin, vincristine, methotrexate)--115 patients. Prognostic factors were well balanced between the two treatment groups. With a 59-month median follow-up, local breast relapses are more frequent in the CMF group, but regional and metastatic recurrences are the same in the two groups. Overall survival is identical. Toxicity is different: alopecia and neurotoxicity are more frequent in the MTV+EVM group, but general and digestive toxicities are equivalent. Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions.
1985年1月至1987年12月，228例乳腺癌小于3厘米的女性接受了手术+/-放疗治疗。她们均有腋窝淋巴结受累（N+）和/或缺乏雌激素和孕激素受体（EPR-）。她们被随机分配到一项辅助化疗试验中，比较9个静脉注射CMF疗程（环磷酰胺、甲氨蝶呤、5-氟尿嘧啶）——113例患者——与由3个MTV疗程（丝裂霉素C、噻替派、长春地辛）加3个EVM疗程（表柔比星、长春新碱、甲氨蝶呤）组成的多药化疗——115例患者。两个治疗组之间的预后因素平衡良好。中位随访59个月时，CMF组局部乳腺复发更频繁，但两组的区域和远处复发情况相同。总生存率相同。毒性不同：MTV+EVM组脱发和神经毒性更频繁，但全身和消化系统毒性相当。CMF组血液学毒性更大，需要更频繁地减少剂量。
